Nektar, NKTR and NASDAQ
Nektar Therapeutics (NKTR) stock surges as Oppenheimer upgrades ahead of key mid-stage trial readout for an eczema drug. Read ...
Full Year 2024 Results Key Financial Results Revenue: US$98.4m (up 9.2% from ...
2d
Zacks Investment Research on MSNNektar Q4 Loss Wider Than Expected, Pipeline in Focus, Stock UpNektar Therapeutics NKTR incurred an adjusted loss per share of 15 cents in the fourth quarter of 2024, wider than the Zacks ...
EDT Nektar (NKTR) up 12% to 91c after Oppenheimer upgrade with $6 targetLight Up your Portfolio with Spark:Easily identify stocks' risks ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results